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Abstract: Diabetic foot ulcers (DFUs) are a serious complication from diabetes mellitus, with a
huge economic, social and psychological impact on the patients’ life. One of the main reasons
why DFUs are so difficult to heal is related to the presence of biofilms. Biofilms promote wound
inflammation and a remarkable lack of response to host defences/treatment options, which can lead
to disease progression and chronicity. In fact, appropriate treatment for the elimination of these
microbial communities can prevent the disease evolution and, in some cases, even avoid more serious
outcomes, such as amputation or death. However, the detection of biofilm-associated DFUs is difficult
due to the lack of methods for diagnostics in clinical settings. In this review, the current knowledge
on the involvement of biofilms in DFUs is discussed, as well as how the surrounding environment
influences biofilm formation and regulation, along with its clinical implications. A special focus is
also given to biofilm-associated DFU diagnosis and therapeutic strategies. An overview on promising
alternative therapeutics is provided and an algorithm considering biofilm detection and treatment is
proposed.
Keywords: biofilms; chronic wounds; combination therapy; multidrug resistance; pathophysiology;
polymicrobial aetiology
1. Introduction
Diabetes mellitus (DM) is one of the most prevalent endocrine diseases worldwide,
characterised by an increase in blood glucose levels caused by defective insulin secretion,
action or both [1]. Officially, diabetes is classified into three major groups, namely, Type 1,
Type 2 and gestational [2]. Type 1 DM or insulin-dependent DM (IDDM) is the result of a
failure of the body to produce insulin, due to destruction of pancreatic β-cells [3]. This type
represents only 5–10% of all diabetes cases and is mostly associated to genetic factors [2].
Type 2 DM, also known as non-insulin dependent DM (NIDDM), represents the most
common type comprising 85% of all cases [2]. This Type results from insulin resistance or
insufficient insulin production, essentially associated with multihormonal disorders [4].
Gestational DM (GDM) is mainly caused by a blockage of insulin action by the pregnancy
hormones, causing insulin resistance and hyperglycaemia [5]. Women with a history of
GDM are more likely to develop Type 2 diabetes later in their lives [5].
The global prevalence of diabetes increases every year. In fact, the number of people
with diabetes between 1980 and 2014 quadrupled, from 108 million to 422 million, and the
numbers continue to escalate [6]. This increase is so fast that diabetes is now considered by
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the World Health Organization (WHO) as a global fast-growing epidemic [6]. According
to epidemiological studies, if the current trend continues, by 2045, 700 million adults will
suffer from the disease, which represents a 51% increase [7,8]. In addition to this global
public health threat, there is a huge economic burden associated. The related annual global
health expenditure will rise 11% from USD 760 billion in 2019 to USD 845 billion by 2045 [8].
In addition to the economic impact associated with this disease, there are other
multifaceted complications that account for more than 50% of these direct costs, such
as nephropathy, neuropathy, retinopathy, atherosclerosis and foot ulcers [9–13]. These
secondary pathophysiological outcomes are a result of a deficiency in the vascular system,
causing inefficient circulation [14]. Among all of these diabetes complications, foot ulcers
are at higher risk to occur, and it is estimated that 20% of hospital admissions among
DM patients result from diabetic foot ulcers (DFUs) [14,15]. DFUs can lead to infection,
gangrene, amputation, and if proper treatment is not provided, can even cause death [14,15].
In fact, once a DFU is developed there is a greater risk of amputation, and it is estimated
that 50–70% of all lower limb amputations (LLAs) are due to DFUs [14]. It is predicted
that in the general population (≥45 years), the incidence of vascular LLA in the diabetic is
eight times higher than in non-diabetic individuals, and when it comes to the age group
≥ 85 years, the incidence in men increases to 15 times higher and 12 times higher in
women than the mean incidence rates of all population groups [16]. Unfortunately, the
COVID-19 outbreak has had a negative impact on healthcare delivery to patients with
DFUs [17,18]. In fact, a study in Naples reported that patients with diabetes admitted to a
Tertiary Care Center for DFU management had a threefold risk of amputation compared to
2019 numbers [19]. LLA has a greater negative impact on the patient’s quality of life than
any other complication of diabetes, such as renal failure or blindness, with depression and
anxiety highly associated [12,20]. Regarding the considerable morbidity associated, it has
been reported that every 30 s, one leg is amputated worldwide due to DFUs [14].
DFUs can be colonised by pathogenic bacteria and infection is favoured by the im-
munological deficiencies related to diabetes [21,22]. The pathogens involved in these
infections vary from aerobic to anaerobic species, which may include Staphylococcus spp.,
Streptococcus spp., Proteobacteria, Pseudomonas aeruginosa and coliform bacteria [14]. In
DFUs, the different microorganisms can exist either in planktonic or sessile state [23]. When
bacteria form biofilms, the cells are embedded in a self-produced polymeric matrix, which
confers them protection from the host’s immune system and from antibiotics [24]. As a
consequence, biofilms in DFUs may be responsible for the delayed healing and consequent
infection chronicity [25–27], despite systemic antibiotic treatment [28].
This review aims to provide insights to DFU causes, predisposition factors, and the
global impact on the economy and society. Furthermore, measures usually applied for the
prevention of new/recurrent DFUs, and the management and treatment of DFU infections
are reviewed. Emphasis will be given to the biofilm’s contribution to DFU infection
exacerbation and persistence. The main tools used for the diagnosis and treatment of
biofilm-associated DFUs are also reviewed.
2. Epidemiology and Risk Factors of Diabetic Foot Ulcers
The diabetic foot is a major medical, social and economic problem, affecting 40 to
60 million people globally [29]. The main risk factors for diabetic foot ulceration are
older age, male sex, Type 2 diabetes, lower body mass index, longer diabetic duration,
hypertension, diabetic retinopathy and a history of smoking [9,30]. DFUs, especially
chronic ulcers, can lead to amputations which can cause a significant decrease in life quality
and an increase in early mortality [8]. The five-year relative mortality after a DFU is 48%,
which is a higher value than that of many types of cancers [31]. However, the reported
frequency of ulceration varies considerably. For example, the prevalence of active DFUs
ranges from 3% in Oceania to 13% in North America, with a global mean prevalence
of 6.3% [30]. This difference is even greater when comparing DFU prevalence among
countries [30]. For example, Belgium has the highest prevalence of DFUs with 16.6%,
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whereas Australia presents the lowest value: 1.5% [30]. These disparities are justified by
some differences in the healthcare systems. For instance, in Belgium, the state supports the
treatment costs, but not the expenses related to preventive treatments, whereas in Australia,
fewer than 50% of diabetic patients have regular foot examinations [32,33].
3. Social and Economic Burden of Diabetic Foot Ulcers
DFUs have a significant impact from both the patient perspectives as well as from a
medical and economic standpoint. Diabetic patients with foot ulcers bear health expen-
ditures five times higher than those without it [34]. In the United States, around USD
17 billion are spent annually for diabetic foot care, while the European Commission (EC)
estimates that these costs are approximately EUR 2.5 billion per year [12,35]. Intangible
costs, those which cannot be measured, also have a significant impact on patient’s lives.
These costs include anxiety, frustration, discomfort, pain, loss of independence, and others
which arise, for example, due to concerns about managing the condition, fear of future
complications and impact on the quality of life [8]. However, early detection and improved
management of diabetes complications will benefit not only the quality of life of individuals
with diabetes, but also the health economy in general [36].
4. Etiopathogenesis of Diabetic Foot Ulcers
The aetiology of DFUs is multifaceted; it results from the simultaneous action of
multiple contributing causes. In addition, because metabolic mechanisms are impaired in
DM, the risk of infection and/or poor wound healing is high [37,38]. Monteiro-Soares et al.
performed a systematic review on the association between independent variables and
DFUs [38]. The authors included 71 studies and evaluated the association between DFUs
and more than 100 independent variables. Diabetic neuropathy, peripheral arterial disease,
foot deformity and previous diabetic foot ulceration or lower extremity amputation were
consistently associated with diabetic foot ulceration development [38]. Of these, peripheral
neuropathy (neuropathic ulcer), peripheral arterial disease (ischemic ulcer), or both (neuro-
ischemic ulcer) were considered the major underlying causes [38]. Moreover, a combination
of these primary risk factors and other causal factors may be involved [39,40]. Other factors
such as poor glycaemic control (which progressively leads to peripheral neuropathies), poor
hygiene habits, lack of regular surveillance of skin integrity, non-premature detection of
injuries and prolonged pressure in specific areas, can also be of relevance and, if controlled
in a timely manner, can prevent wounding or wound progression. However, these are
mainly under the patients’ control [9,41].
4.1. Peripheral Neuropathy
Diabetic peripheral neuropathy is characterised by the impairment of normal activities
of the nerves, causing ulceration due to trauma or excessive pressure on a deformed foot
without protective sensitivity [42]. The prevalence of diabetic peripheral neuropathy
ranges from 16% to as high as 66% [43]. In neuropathy, hyperglycaemia increases the
action of the enzymes aldose reductase and sorbitol dehydrogenase, resulting in the
conversion of intracellular glucose into sorbitol and fructose. As these products accumulate,
myoinositol synthesis of nerve cells is reduced, affecting nerve conduction [44]. The damage
of innervations leads to an imbalance between flexion and extension of the affected foot,
resulting in anatomical deformities with abnormal bony prominences and pressure points
which cause gradual ruptures of the skin and ulceration [44]. Diabetic neuropathy is
manifested in motor, autonomic and sensory components of the nervous system [40].
Motor neuropathy causes dysfunctions in leg muscles, resulting in the protrusion of
abnormal bones, alteration of the normal foot architecture and foot deformities, such as
hammertoes and hallux rigidus [45]. Damage to the innervation of leg muscles causes an
imbalance between flexion and leg extension, resulting in deformity and change in pressure
points [46]. Progressively, it will lead to skin damage that develops into ulcers. Autonomic
neuropathy is manifested by the interruption of microvascular blood flow and sudomotor
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function that results in dry skin without sweating, which, in turn, triggers fissures and
skin crust and makes the foot vulnerable to minimal trauma [47]. Sensory neuropathy
presents a loss of protective sensation, resulting in susceptibility to physical and thermal
trauma as well as increased risk to developing foot ulcers [48]. In short, diabetic peripheral
neuropathy results not only in the loss of the proprioception of foot position, but also in
the loss of pain and pressure sensation. This sensory deficit may lead to the presence of an
unknown ulcer [44]. Once the protective layer of the skin is damaged, tissues are exposed
to bacterial colonisation and are thus more prone to form complex microbial communities
such as biofilms [42].
4.2. Peripheral Arterial Disease
Peripheral arterial disease contributes to the development of foot ulcers in up to 50%
of cases [49,50]. In peripheral arterial disease, hyperglycaemia causes vascular endothelial
dysfunction as well as decreased vasodilator production by the endothelium, which results
in blood vessel constriction [51]. Hyperglycaemia in diabetes increases thromboxane
A2, a vasoconstrictor with prothrombotic properties that results in an increased risk of
hypercoagulability [52]. Hypertension and dyslipidaemia also contribute to the occurrence
of peripheral arterial disease [53]. These factors cause occlusive arterial disease, which
results in ischaemia of the lower extremities and increases the risk of developing ulcers [44].
In this way, the formed ulcers can be easily infected, evolve into gangrene, and end up
with a lower leg amputation (below the knee) [54].
5. Preventive Measures for Diabetic Foot Ulcers
According to International Working Group on the Diabetic Foot (IWGDF) guidelines
(2019), some key points can help to prevent DFUs: (i) identify the at-risk foot; (ii) regular
inspection and examination of the at-risk foot; (iii) educate the patient and the patient’s
family; (iv) ensure the wearing of appropriate footwear; and (v) treat risk factors for
ulceration [55]. These key points should be address by a specialised team of healthcare
professionals [55]. The early detection and proper management of DFUs will have benefits,
not only for people with diabetes, but also for the wider health economy [8].
In a first instance, a regular examination of the feet should be performed. In the
absence of symptoms, the risk of foot ulceration is low, but this cannot be neglected, and
an annual examination must be performed [55]. Knowledge of foot self-care practices
and the recognition of signs of ulceration should be taught to people with diabetes [55].
Minor changes in behaviour, such as shoe replacements, are also important. Wearing
inappropriate shoes or walking barefoot are the main causes of foot trauma that lead
to foot ulceration in diabetics [38]. It is recommended to use tailored shoes to suit any
change in the foot structure or foot biomechanics [56]. Treating any modifiable risk factor
or pre-ulcerative sign is also recommended. This includes removing corns; protecting the
bubbles or draining them if necessary; treating ingrown or thickened nails; and prescribing
appropriate therapeutics for fungal infections. The treatment must be continued until these
abnormalities disappear, without recurrence. If these preventive measures fail, surgical
intervention should be considered [55].
6. Management and Treatment of Diabetic Foot Ulcers
Predicting the appearance of chronic wounds such as foot ulcers in diabetic patients
is almost impossible. Therefore, when preventive measures fail and the development of
DFUs occurs, appropriate treatment should start immediately [57]. The primary purpose
of basic wound care involves keeping the wound base free of nonviable tissue, facilitating
a measurable and meaningful wound size reduction, which ultimately will lead to its
healing [58]. The healing of DFUs requires not only the control of the infection, following
the universal principles of hygiene and proper dressing of the ulcer, but also the adequate
restoration of the vascularity and other extra care regarding the metabolic regulation
of glycaemia and lipids, the cessation of smoking and weight reduction [59]. Indeed,
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ulceration usually occurs in the high-pressure bearing area of the foot [60]. Patients with
diabetes have higher peak plantar pressures, along with repetitive pedal stress caused by
bone and structural abnormalities of the foot in the presence of neuropathy and peripheral
arterial disease [61,62]. As a result, the redistribution of constant plantar pressure is of
utmost importance in managing a DFU in remission [63]. In DFU treatment, the regular
wound maintenance implies several steps, including offloading, debridement, antimicrobial
therapy and dressing.
Offloading is the most important element for the management of neuropathic ulcers.
It is an intervention characterised by the relief of plantar pressure, because it avoids high-
pressure load in the ulcerated area while still allowing the patient to walk [64]. This pressure
redistribution prevents any trauma to the tissue and facilitates wound healing [65,66]. The
most effective offloading device is total contact casting (TCC) [48]. This device is designed
and moulded carefully to the shape of the foot, which thereby forces compliance, reduces
activity levels, and consequently, improves wound healing [67]. Some evidence suggests
that TCC boosts the reduction in wound pressure, prompting healing rates between 73%
and 100% [68–72].
Another critical step in DFU management which should be performed before the
application of any wound closure treatment is debridement [73]. Debridement is a therapy
that involves the removal of nonviable tissue and debris at the wound margins [74]. The
reasoning for serial debridement is to activate senescent cells, stimulate the release of
growth factors, remove inflammatory factors, and reduce bioburden [75]. It also helps in
the elimination of the base of abnormal injury, callus (epidermal hyperkeratosis), necrotic
tissue and bacterial elements that inhibit wound healing [76]. There are different debride-
ment methods, namely, surgical (for sharp debridement), biosurgical (use of maggots),
autolytic (use of hydrogels, hydrocolloids and transparent films), biochemical (use of en-
zyme preparations), chemical (use of antiseptics, polysaccharide beads and pastes) and
mechanical (use of hydrodebridement) [77]. Among all these debridement methods, the
one considered the gold standard, and thus contributing the most to wound healing, is the
surgical or sharp debridement method [48]. This technique is a rapid and effective way
to remove dead tissue. Ideally, this procedure should be performed in combination with
other treatment approaches, such as growth factors or cell-based therapies.
Typically, due to the high incidence rate of DFU infections, it is necessary to combine
the conventional methodologies described above with an appropriate antibiotic regimen.
This initial antibiotic treatment is generally empirical to cover the most commonly infecting
microorganisms. However, this routine should be revised according to the severity of the
infection or to the available microbiological data [78,79]. In fact, this information should
be a subject of detailed study through microbiological cultures in order to determine the
causative pathogens, and most importantly, their susceptibility to antibiotics [78,79]. In
fact, there are some recommendations proposed by the Infectious Diseases Society of
America (IDSA) for empirical antibiotic regimens considering the associated pathogen
and the clinical severity of the infection (Table 1). According to these recommendations,
narrow-spectrum oral antibiotics must be administered for mild infections, oral or par-
enteral antibiotics for moderate infections, and broad-spectrum parenteral antibiotics for
severe infections. The empiric regimen should always include antibiotics against strains
of Staphylococcus and Streptococcus species and, in some specific situations, include an-
tibiotics against Gram-negative rods, methicillin-resistant Staphylococcus aureus (MRSA),
Pseudomonas spp., multidrug-resistant (MDR) bacteria and anaerobes [80]. Empirical antibi-
otic therapy can be continued or adjusted according to the culture results and the patient’s
clinical response. If a clinical improvement is observed and there is no serious infection,
empirical treatment can be continued. This procedure is adopted even if the antibiotic
susceptibility results show that some or all isolated microorganisms are resistant to the pre-
scribed agents [81]. Likewise, if it is a multispecies culture, it may be sufficient to treat only
the likeliest pathogens (e.g., S. aureus, Streptococcus species and Enterobacteriaceae) [82,83].
However, if the infection does not respond, the antibiotics initially selected should be
Int. J. Mol. Sci. 2021, 22, 8278 6 of 25
replaced with alternatives with a broad-spectrum of action. If the infection worsens further,
despite proper antimicrobial therapy, other options should be considered, such as surgery
or the use of advanced therapies.
Table 1. Suggested antibiotics for the empirical treatment of infected DFUs based on the clinical
severity. Adapted from Lipsky et al. [80].






































































plus one of the following:
aminoglycoside,
or a carbapenem
A major breakthrough for DFU management has been the design of novel dressings.
Ideally, dressings should alleviate symptoms, provide wound protection and help wound
healing [84]. Dressings have been engineered to guarantee a moist environment (favourable
for healing), while also controlling microbial growth, allowing gaseous exchange, and
thermally insulating the wound [85,86]. When choosing the dressing for an infected DFU,
some factors must be taken into consideration: it should be comfortable and adequate
for the patient as well as help to alleviate or at least not worsen the pain, especially
during dressing changes; it should aid in the management of the infection itself; allow the
observation of the wound; provide mechanical protection and conformability; and should
be cost-effective [87]. There are a wide variety of dressings commercially available for the
treatment of DFUs, and new products are frequently being developed and released, each
one aimed at different aspects of healing [85,88]. In Table 2, different classes of dressings
and their advantages/disadvantages are presented.
Int. J. Mol. Sci. 2021, 22, 8278 7 of 25
Table 2. Classes of dressings used in DFUs. Adapted from Hilton et al. [85] and Kavitha et al. [88].
Dressing Classes Advantage(s) Disadvantage(s)








Hydrocolloids Absorbent; Can be left for several
days; Aids autolysis
Avoid use on infected wounds;
Facilitates maceration;
Unpleasant odour
Hydrogels Good absorbent; Aids autolysis;
Donate liquid




Can adhere to wound; Occasional
dermatitis due to the adhesive
Alginates Highly absorbent; Bacteriostatic;
Haemostatic; Useful in cavities
Require wetting before removal
Iodine preparations Antiseptic; Moderately absorbent Iodine allergy; Discolours wounds;
Avoid in cases of thyroid disease
or pregnancy
Silver-impregnated Antiseptic; Absorbent Cost
Despite some success in the management of DFUs using conventional methods, there
are still some cases without desired outcomes. For these situations, advanced therapies
have been developed either alone or in combination with these conventional techniques
to increase the healing rates, reduce the treatment time, and decrease the probability of
amputation. Among the most advanced therapies used are hyperbaric oxygen therapy
(HBOT), negative pressure wound therapy (NPWT), bioengineering skin (BES) substitutes
and growth factors.
HBOT is a methodology that involves the daily intermittent administration of 100%
oxygen to the wound through an airtight vessel at a pressure higher than atmospheric
(2–3 atm) [89,90]. As a result, this technique will increase the concentration of dissolved
oxygen in plasma; therefore, this will lead to a rise in the diffusion of oxygen into tissues [89].
The exact mechanism of action of HBOT is not yet fully understood; however, there are
some reports suggesting that improved healing is caused by the better replication of
fibroblasts, endothelial cells and keratinocytes in an oxygen-rich environment, and the more
effective killing of bacteria by leukocytes [48,91]. Despite the reports of an increased healing
rate, this technique is not recommended as an adjuvant therapy. This is a technique which
does not substitute the conventional treatment and, in addition, has huge associated costs
(between USD 50,000 and 200,000) [15]. Furthermore, and based on a systematic review
conducted by the National Institute for Health and Clinical Excellence (NICE) Guidelines
Development Group in the United Kingdom, it was concluded that the data available were
not robust enough to demonstrate that this technique is indeed cost-effective [92].
NPWT is considered to be an innovative treatment for DFUs. It is based on the use of
a specific pump to create a localised sub-atmospheric pressure that will help the wound
to heal [48]. Within this process, a closed system is created by using polyurethane or
polyvinyl alcohol foam dressings, which are fitted to the wound surface, and an adhesive
drape for coverage [15,48]. The suction generated by the pump will allow the collection
of wound fluids, discharge and exudate [15,46]. This therapy has been shown to enhance
oedema and exudate removal, to reduce bacterial colonisation, and to improve the blood
flow [93]. There is promising evidence of the success of NPWT in patients with DFUs;
however, it appears only to be effective as a postsurgical treatment [15]. NPWT should
only be performed after debridement, and continued until the formation of granulated
tissue [48]. Studies have suggested that NPWT significantly reduces healing times and
increases the healing rate [94,95].
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Another relatively recent therapeutic method used to manage DFUs involves the use
of BES substitutes [96–98]. This method comprises the replacement of the degraded milieu
of extracellular matrix by a new matrix with cellular/acellular components [15]. These BES
substitutes can be classified into three major groups, allogenic cell-containing, autologous
cell-containing and acellular matrices [48]. The first two include matrices containing living
cells, such as keratinocytes and fibroblasts, whereas the latter comprises the release of
growth factors [48]. Basically, this product is based on scaffolds that are seeded with human
cells or growth factors which are then cultured in vitro. This culture will function as a
delivery system that allows the cell-secreted matrix and growth factors to accumulate in the
scaffold and actively be secreted at the wound bed [96,98]. Currently, there are some BES
products which have been approved, namely, AlloDerm® (LifeCell Corporation, Branch-
burg, NJ, USA); Apligraf® (Graftskin, Organogenesis Inc., Canton, MA, USA); Dermagraft®
(Advanced Biohealing Westport, CT, USA); GRAFTJACKET® (Wright Medical Group Inc.,
Arlington, TN, USA); Hyalograft® 3D (Fidia Advanced BioPolymers, Abano Terme, Italy);
Laserskin® (Fidia Advanced BioPolymers, Abano Terme, Italy); OASIS® (Cook Biotech,
West Lafayette, IN, USA); OrCell® (Ortec International Inc., New York, NY, USA); and
TranCell® (CellTran Ltd., Sheffield, UK) [48]. Despite all the advantages of BES mentioned
above, it cannot be used alone for the treatment of DFUs due to wound-specific characteris-
tics that may affect transplantation, as is the case with peripheral ischaemia [15]. Therefore,
for this procedure, preparation of the wound bed including surgical revascularisation,
decompression and infection control are necessary steps [15]. Taking everything into con-
sideration, it appears evident that this therapy may lead to elevated long-term costs and
treatment periods.
The use of growth factors is also reported to benefit DFU treatment, particularly
of non-infected wounds [48]. This therapy includes the use of growth factors such as
fibroblast growth factor, vascular endothelial growth factor, platelet-derived growth factor
(PDGF), insulin-like growth factor (IGF1, IGF2), epidermal growth factor and transforming
growth factor beta [15,99]. Among these growth factors, the only one approved by FDA is
recombinant human PDGF, also known as becaplermin or Regranex [15,48]. This product
is a hydrogel containing human platelet-derived growth factors which, when used in
combination with debridement, have been demonstrated to increase ulcer healing [100–102].
Initially, this gel produced some positive results; however, it has been associated with an
increased incidence of cancer, especially in patients treated with high doses [103]. Therefore,
the FDA published a warning note regarding the use of high doses of becaplermin.
Failures or delays of DFU healing in patients that received optimal standards of care
and still have evident clinical infection can be explained by the presence of a biofilm [104].
Infections related to biofilm occurrence are usually different from those promoted by the
same microorganisms in a planktonic state; therefore, the therapeutic schemes are usually
ineffective, resulting in non-healing chronic wounds [105].
7. The Role of Biofilms in Diabetic Foot Ulcers
The skin microbiota is essential for the regulation of the host immune system, the
maintenance of epithelial barrier function, and protection against invading pathogenic
microorganisms [106]. After injury, skin microbiota and pathogenic species may colonise
the wound and proliferate [107]. In fact, studies have demonstrated that species isolated
from chronic wounds are commensal on healthy skin [41,108–110]. For example, Park et al.
analysed the microbiota of diabetic foot wound (DFW) tissue compared with normal foot
skin in the same patients [110]. The authors found a myriad of Actinobacteria, Staphylococcus,
Corynebacterium, and Propionibacterium species in normal samples compared to the infected
tissue, and a relative abundance of anaerobes (Bacteroides and Enterococcus) and Pseudomonas
species in wound tissues. Anaerobes in wounds can impair wound healing and increase
the severity of infection [111]. These results are in agreement with other studies [108–110],
suggesting that DFUs are associated with polymicrobial colonisation [112,113], containing
more anaerobic bacteria than other wounds [114]. In addition to the expression of several
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virulence factors, polymicrobial communities can be organised into biofilms, responsible
for DFU chronicity [112,115].
Biofilms are complex communities, consisting of microbial cells embedded in a self-
produced matrix of extracellular polymeric substance (EPS). This matrix is composed of
proteins, lipids, nucleic acids, polysaccharides and other components which confer the
ability of bacteria to adhere to biotic or abiotic surfaces [115,116]. Biofilms are ubiquitous in
nature and have a considerable impact on the healthcare sector. It is estimated that around
65% of all bacterial infections in humans are associated with biofilms [73]. Actually, they
have been associated with several different illnesses, such as nephrolithiasis, endocarditis,
cystic fibrosis, oral infections, and infections associated with indwelling devices [117].
In addition, biofilms exist in both chronic and acute wound infections [118], offering
some ecological and physiological advantages to bacteria [119]. In fact, biofilms provide
a physical protection to bacteria, which prevents antimicrobial agents (disinfectants and
antibiotics) from penetrating the complex structure of biofilms, decreasing the concentration
of antimicrobials acting against the embedded cells [120]. Additionally, due to close cell–cell
contact in biofilms, horizontal gene transfer of antibiotic-resistant genes is facilitated [121].
In addition, due to the characteristics mentioned above, during a biofilm infection, host
immune responses generated are largely ineffective, which leads to recurrent or chronic
infections [122,123].
7.1. Biofilm-Associated Diabetic Foot Ulcer Infections
Biofilms have a crucial role in diabetic foot infections because the colonising bac-
teria act synergistically, creating a symbiotic environment favourable for the infection
progression and, therefore, for the generation of a chronic wound [23]. Bacteria present
in chronic wounds find the environment ideal for the formation of these polymicrobial
sessile communities [105]. Furthermore, necrotic tissue and debris present in DFUs allow
bacterial adhesion and biofilm formation [105]. In contrast to planktonic cells, biofilms are
almost impossible to treat and eradicate [112,124,125]. In fact, biofilm formation is consid-
ered one of the reasons why wound infections treatment with conventional antimicrobial
agent fails [116,126]. The presence of biofilms has been found in approximately 60–80%
of chronic wounds and 6% of acute wounds, which strongly implies their contribution
to hinder wound healing [127]. Bacteria in planktonic state express virulence factors that
favour acute infections, whereas the sessile state is related to chronic infections [115,128].
A chronic inflammatory response is generated in an attempt to clean the biofilm
from the wound. Thus, there is an accumulation of neutrophils and macrophages around
biofilms, which secrete high levels of reactive oxygen species (ROS) and proteases [129].
Proteases can help to break down the attachment between the biofilm and the tissue [129].
However, ROS and proteases can impair healing by damaging normal or regenerating
tissues, and interfering with immune system proteins and cells [130]. Neutrophils play
an important role in the wound healing process by removing bacteria, foreign material,
and necrotic tissue, and releasing cytokines to promote revascularisation and fibrosis [105].
On the other hand, the prolonged existence of neutrophils can lead to the release of
inflammatory factors, ROS and proteinases that degrade the extracellular matrix and
proteins involved in the healing cascade, causing a delay in wound healing [131]. Matrix
metalloproteinases (MMPs) are an example of proteinases that play a major role in wound
healing [132]. MMP levels decrease through the normal wound-healing process, whereas
the exaggerated inflammatory phase in chronic wounds leads to an excess of proteases and
inflammatory cytokines released by neutrophils and macrophages [133–135]. Lobman et al.
found that the levels of some MMPs (MMP-1, MMP-8, MMP-9 and activated MMP-2)
were significantly higher in DFUs [136]. In contrast, the level of the tissue inhibitor of
MMP (TIMP), TIMP-2, was significantly lower compared to acute wounds from non-
diabetic patients. These results suggest that impaired healing in DFUs can be caused by
the imbalance between an excess of MMPs and a decrease in TIMPs [134]. Recently, Chang
and Nguyen observed different effects on the healing process using different selective
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inhibitors for MMP-8 and MMP-9 proteinases, identified from the wounds of diabetic
mice and humans [137]. Their investigation showed that infection increases MMP-9 levels,
incrementing inflammation and decreasing angiogenesis, whereas MMP-8 is beneficial for
wound repair. That said, the authors suggest that the best strategy for treating DFUs is
to selectively inhibit the MMP-9 proteinase without affecting the beneficial MMP-8 [137].
Research is needed on the influence of MMPs and biofilms on the healing of chronic
wounds. However, evidence suggests that with treating chronic inflammation, including
‘trapping’ MMPs and implementing effective sustained debridement, MMPs and biofilm
production will be reduced [138].
The impairment of neutrophils also appears to be caused by quorum sensing (QS)-
regulated proteases [139]. Active QS mechanisms associated with P. aeruginosa in immuno-
compromised patients with chronic infections [140] results in an accumulation of circulating
neutrophils close to the biofilm [141]. Jensen et al. observed that chronic venous leg ulcers
containing P. aeruginosa had a significantly higher number of neutrophils than wounds
containing S. aureus, suggesting once again that biofilms are surrounded or overlaid by
neutrophils, but they are not penetrated and killed by them [140]. Regarding macrophages,
normally, they are activated by the presence of microorganisms and their by-products
such as lipoteichoic acid (LTA), lipopolysaccharide (LPS) and chemical mediators [142].
Macrophage activation promotes the release of pro-inflammatory cytokines and cytotoxic
molecules including tumour necrosis factor-α (TNF-α), interleukin (IL)-1, IL-6, IL-8 and
nitric oxide (NO) [143]. The role of macrophages in chronic biofilm infection is still unclear.
Some studies suggest that macrophages release more proinflammatory cytokines (TNF-a,
IL-6) and NO levels when exposed to planktonic cells than to biofilms [142]. Therefore,
chronic inflammatory response is not always successful in removing the biofilm [105].
Instead, it has been hypothesised that chronic inflammation may benefit the biofilm by
inducing an ineffective inflammatory response [144].
7.1.1. Clinical Profile
A limited number of studies correlate biofilm formation with DFUs. According to
Zubair et al., 77.1% DFU patients had an infection of biofilm-producing bacteria, and the
presence of a biofilm was associated with gender, neuropathy presence, osteomyelitis, ulcer
duration, ulcer grade, necrotising ulcer and ulcer size [145]. Malik et al. determined that
the overall biofilm-producing infection rate among DFUs was 67.9% and involved the same
risk factors highlighted by Zubair et al. [145,146]. Vatan et al. found that the overall rate of
biofilm production among 339 wound isolates was 34% [147]. Once again, the same risk
factors for biofilm formation in DFU were observed, except for ulcer size, which was not
assessed. Additionally, Pugazhendhi and Dorairaj demonstrated the correlation of biofilm
formation with the clinical characteristics of DFU [148]. In this way, ulcer duration, size,
nature and grade were associated with biofilm production. Therefore, biofilm formation in
DFUs appears to be mainly linked with all the factors mentioned above (Table 3) [146–148].
Many of the bacterial species found in chronic wounds are commensals on the skin [41].
This transfer of microorganisms from healthy skin to the wound tissue can increase infection
severity [108–110]. Biofilm formation in DFUs is more commonly associated with Gram-
negative bacteria than those which are Gram-positive (Table 4). In the study by Banu et al.,
the rate of biofilm formation in DFU isolates was 46%, from which 26.5% were P. aeruginosa
and 10.5% were E. coli strains [149]. Mottola et al. demonstrated that Pseudomonas strains
had the highest rate of biofilm production, followed by Corynebacterium, Acinetobacter,
Staphylococcus and Enterococcus strains [150]. Additionally, Vatan et al. verified that the
most common biofilm-associated bacteria in DFUs were A. baumannii (65%), P. aeruginosa
(52%) and Klebsiella spp. (40%) [147].
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Table 3. Relationship between biofilm formation and clinical profile. Comparison of 4 studies
(Zubair et al. [145]; Malik, Mohammad and Ahmad [146]; Pugazhendhi and Dorairaj [148]; Vatan et al. [147]).
Study 1 Study 2 Study 3 Study 4
n * 57 162 - 160
Biofilm + 44 110 115 -
Gender (male) 32 76 - 82
Age distribution 44.6 ± 7.3 - 62.7 -
>40 years 64.8% 70.0% - -
Diabetes duration
(average year) 14.9 ± 2.6 - 16.0 ± 0.0 -
Ulcer duration 39.6 ± 2.6 - 48.2 ± 42.3 -
>1 month 52.6% 75.0% -
Hospital stay
>1 month 59.5% 75.0% - -
Amputation 24.5% 80.4% 42.0%
Ulcer size
<4 cm2 64.9% 69.3% - 89.0%
Comorbidities
Hypertension 72.7% 80.4% 34.0% 16.0%
Nephropathy 77.1% 77.7% 37.0% 25.0%
Retinopathy 68.7% 52.4% 3.0% 22.0%
Neuropathy 89.4% 57.3% 34.0% 18.0%
Osteomyelitis 88.8% 65.0% - -
Status
Death 3.5% 72.2% 38.0% -
* The n value represents the number of diabetic patients with foot ulcers, infected or not infected with biofilms.
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7.1.2. Diagnosis and Treatment Using Conventional Methods
Contrary to planktonic microorganisms that can be easily identified through cultivation-
based approaches, biofilm identification requires specific techniques. Magana et al. de-
scribed current methods for bacterial biofilm characterisation, monitoring and quantifi-
cation in detail [151]. However, some of these methods are not available in most clin-
ical microbiology laboratories [152]. Additionally, there is an evident lack of tests for
the detection of biofilms in wounds, as well as quantifiable biomarkers to confirm their
presence. Consequently, the search for biofilms in clinical samples is difficult and time-
consuming [124]. To work around this flaw, some clinicians use ‘clinical cues’ of the biofilm
presence through naked eye observations. Such signs include the presence of a shiny,
translucent and slimy layer on the non-healing wound surface; the presence of slough or
fibrin; and the presence of gelatinous material that quickly returns after removal [104].
Figure 1 provides a list of the main clinical and laboratory indications for the diagnosis of
biofilm infections according to the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) guidelines.
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Figure 1. Clinical and laboratory indications for diagnosis of biofilm infections—ESCMID General
Features. Based on Høiby et al. [124].
Inaccurate sample collection can frequently lead to false-negative results [124]. Tissue
biopsies are considered the most reliable type of sample to reveal biofilms in wounds [124].
The use of swabs for the collection of biofilm samples from the wound surface is not
recommended [124]. In fact, contamination can occur from the skin flora, in addition
to the strong adherence of biofilms to the epithelium and growth of anaerobes in deep
tissues [80,118].
The detection of biofilms can be performed through routine light microscopy analysis
and routine staining methods, including Gram staining, which stains tissues/mucus,
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inflammatory cells, bacteria and the biofilm matrix; and it requires evidence of an infectious
process, such as the presence of leukocytes and microbial aggregates embedded in a self-
produced matrix distinct from the surrounding tissue [153]. Confocal laser scanning
microscopy (CLSM) and scanning electron microscopy (SEM) are the most appropriate
techniques to reveal biofilms in biopsies, but they are not available in clinical settings for
routine diagnostic work [124]. For instance, in the study performed by Johani et al., SEM
and peptide nucleic acid fluorescent in situ hybridisation (PNA-FISH) techniques combined
with CLSM were employed to analyse DFUs samples from 65 patients [104]. They identified
the presence of densely aggregated bacteria often surrounded by an extracellular matrix in
all samples, confirming that biofilms are ubiquitous in DFUs. Furthermore, the specific
microscopic identification of biofilm microorganisms can also be performed by means of
species-specific FISH probes and fluorescence microscopy [153]. In contrast, conventional
culture methods or culture-independent methods based on PCR techniques (16S rRNA gene
amplification, denaturant gradient gel electrophoresis, bacterial tag-encoded FLX amplicon
pyrosequencing) [154,155] cannot discriminate between planktonic and biofilm-growing
bacteria [156–158].
According to the current guidelines [81,159], the treatment of biofilm-associated DFUs
infections should be based on a biofilm-based wound treatment (BBWC) that emphasises
a “step-down-then-step-up” approach. This treatment line begins with a combination of
the mechanical debridement of biofilms in an aggressive manner and the administration
of topical antibiotics effective for killing residual bacteria from the biofilm. As soon
as the biofilm bioburden level is reduced, the inflammatory response (neutrophils and
macrophages) and the high levels of proteases and ROS will also decrease. This will allow
the wound to evolve from a chronic state to an active healing state. At this point, the
frequency of topical treatments can then “step down” but not stop completely. Finally,
because the wound bed is “biofilm-free”, topical treatments can “step up” advanced
wound treatments, which will effectively stimulate healing [152]. Here, we propose an
algorithm for the detection and treatment of biofilms in DFUs (Figure S1) based in BBWC
that emphasise a “step-down-then-step-up” [159–161].
7.1.3. Unconventional Therapeutic Strategies
Biofilms have an important role in the aetiology and treatment failure of DFUs, which
require new approaches to combat this kind of infections, particularly when MDR bacteria
are involved [41]. To overcome this hurdle, alternative strategies and approaches to deal
with biofilm-associated infections are being investigated. Unfortunately, there have been
few studies that focused on the treatment of biofilm-associated DFUs. A search on SCOPUS
(2021) with the words: “Antibiofilm diabetic foot ulcer” in the title, keywords and abstract
only displayed eleven research items: three reviews [118,162,163]; seven research articles
about new antibiofilm approaches [164–170]; and one about the design of antibiofilm
peptides [171]. Thus, in this review, the most promising molecules and techniques to
combat biofilm formation or to disaggregate already established mature biofilms, and
that can be used in the prevention/control of biofilm-associated DFU infections, will be
summarised (Table S1). They include antimicrobial peptides (AMPs), bacteriophages,
phytochemicals, nanoparticles and photodynamic therapy (PDT).
AMPs represent a very promising approach as an alternative to antibiotics for treat-
ing chronic biofilm-based infections [172–182]. AMPs have the ability to interfere with
various stages of the biofilm mode of growth, which can be related to their different
mechanisms of action [183]. For example, peptide 6K-F17 can interact with the EPS pro-
duced by P. aeruginosa, leading to reductions in biofilm formation [184]. On the other
hand, human cathelicidic LL-37 can prevent the biofilm formation of P. aeruginosa in three
ways [185]. First, LL-37 reduces the initial cell attachment of P. aeruginosa to the surface,
resulting in fewer bacteria involved in the early stages of biofilm development [185]. Sec-
ondly, LL-37 promotes twitching motility mediated by the type IV pili, by stimulating
the expression of genes related to type IV pilus biosynthesis and function [185,186]. In-
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creased surface motility can cause bacteria to wander across the surface instead of forming
biofilms, resulting in thin and flat biofilms (without a mushroom-like structure) [187,188].
Thirdly, LL-37 affects Las and Rhl, the two major QS-systems of P. aeruginosa. Another
example is the interference of some AMPs with the signalling nucleotides guanosine
5′-diphosphate 3′-diphosphate (ppGpp) and (p)ppGpp that regulate the expression of a
plethora of genes [189,190], which, in turn, are important for biofilm formation [191]. The
AMPs IDR-1018, DJK-5 and DJK-6 can block the synthesis and trigger the degradation
of (p)ppGpp in both Gram-positive and Gram-negative bacteria, which may result in
the reduction in biofilm formation [192–194]. Additionally, these peptides can act syner-
gistically with some conventional antibiotics (e.g., ceftazidime, ciprofloxacin, imipenem
and tobramycin) against Gram-negative pathogens, reducing the antibiotic concentrations
required for complete biofilm inhibition up to 64-fold [192,195].
Due to ineffective antibiotic therapy to prevent and control biofilm infections, an-
other strategy that has aroused interest is phage therapy [196–201]. Bacteriophages are
naturally occurring viruses that can infect and kill bacteria [202]. Unlike many antibiotics,
bacteriophages are able to target bacteria within biofilms without inducing resistance [203].
Bacteriophages can be lysogenic when they coexist with the host by inserting themselves
into the bacterial genome, or lytic when they destroy the host by replication. Lytic bacte-
riophages are the most suited type for therapeutic use [203]. For example, bacteriophage
ZCKP1 was tested in vitro to evaluate its lytic activity against an MDR K. pneumoniae
KP/01, isolated from DFUs [204]. ZCKP1 bacteriophage had the ability to reduce the
bacterial counts of host bacteria by ≥2 log10 CFU/mL at 25 ◦C, and consequently, the
biofilm mass (>50%) [204]. Bacteriophages can be used individually or in a combination
of multiple bacteriophages with different host ranges and directed to different receptors,
the so-called bacteriophage cocktails. Bacteriophage cocktails allow a greater spectrum of
activity and prevent the development of bacterial variants resistant to their action [205].
Alves et al. studied the prevention of P. aeruginosa PAO1 biofilm formation using a cocktail
of six phages [206]. Two biofilm models were studied, one static and one dynamic, and
the bacteriophage cocktail was assessed for its ability to reduce and disperse the biofilm
mass. For the static model, more than 95% of biomass was eliminated after 4 h of contact
with the bacteriophage suspension. In the flow biofilm model, a slower rate of activity
was observed, but 48 h after addition of the bacteriophage cocktail the biofilm was dis-
persed, promoting a reduction of >4-log [206]. In addition, bacteriophages can also be
combined with antibacterial agents, such as antibiotics, to improve the effectiveness against
biofilms [201,207–209]. Rahman et al. combined the bacteriophage SAP-26 with three
different antibiotics (rifampicin, azithromycin and vancomycin) for the control of S. aureus
biofilms [207]. The best result was observed for the combination SAP-26/rifampicin after
24 h of treatment, disrupting the biofilm matrix and promoting a 4-log reduction [207].
Chaudhry et al. tested the combination of two bacteriophages (NP1 and NP3) with an-
tibiotics from five distinct classes (ceftazidime, ciprofloxacin, colistin, gentamicin and
tobramycin) against P. aeruginosa biofilms [208]. Biofilms were treated in one of two ways:
the bacteriophages and antibiotics were simultaneously added; or the bacteriophage mix-
ture was added first and then antibiotics were added with a delay of 4 or 24 h. A significant
effect was observed when bacteriophages were added first and only after 24 h, when
gentamicin or tobramycin were added (1.5-log and 2-log reductions, respectively) [208].
Similarly, Akturk et al. evaluated the synergistic activity of the bacteriophage EPA1 in com-
bination (simultaneous and sequential) with different antibiotics (gentamicin, kanamycin,
tetracycline, chloramphenicol, erythromycin, ciprofloxacin, and meropenem) against mono
and dual P. aeruginosa and S. aureus biofilms [209]. These authors found an improvement
in the killing effect when EPA1 and antibiotics were applied simultaneously. Moreover, a
biofilm reduction below the detection limit was observed when gentamicin or ciprofloxacin
were added sequentially after 6 h of bacteriophage treatment. For dual-species biofilms,
increasing the gentamicin concentration was needed to obtain a similar killing effect as in
mono-species [209].
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Phytochemicals (molecules from the secondary metabolism of plants) are consid-
ered a green and sustainable source of effective antibiofilm molecules [210]. The use of
phytochemicals for the control of multi-resistant biofilms has already been extensively
reviewed [210–216]. Due to their great structural diversity, phytochemicals are associated
with a multi-target mode of action, without imposing selective pressure on bacteria [210].
Borges et al. observed that ferulic acid and gallic acid were effective in the prevention
and control of biofilms of E. coli, Listeria monocytogenes, P. aeruginosa and S. aureus [217].
Monte et al. investigated the mode of action of 7-hydroxycoumarin and indole-3-carbinol
against E. coli and S. aureus biofilms, and observed that both phytochemicals affected the
motility and QS activity [218]. Ouyang et al. observed a significant inhibition of biofilm
formation and production of virulence factors, including pyocyanin, protease and elas-
tase in P. aeruginosa by quercetin [219]. In addition, they detected transcriptional changes
associated with QS and observed that the expression levels of lasI, lasR, rhlI and rhlR
were reduced [219].
Nanoparticles (NPs) have been extensively examined as drug delivery systems for the
treatment of wound infections [220,221]. Due to the biofilm EPS and its ability to hijack,
inactivate, or inhibit the action of antibiotics, there is a need to design drug delivery systems
for the treatment of chronic infections [222]. A delivery system will make it possible to
“protect” the drug, allowing the release of the drugs in a controlled manner [223–225]. NPs
are usually classified into metallic NPs, nonmetal NPs, polymeric NPs, lipid NPs, quan-
tum dots, and ceramic NPs. This review focuses only on one type of metallic NPs, silver
NPs (AgNPs), because their antimicrobial efficacy and potential for use in the treatment
of chronic infections has been extensively reported [226,227]. Martínez-Gutierrez et al.
evaluated the antibiofilm activities of AgNPs against P. aeruginosa PAO1 biofilms generated
under static conditions and high fluid shear conditions [228]. They observed log reduc-
tions inversely related to fluid shear: for biofilms formed under fluid shear, inhibition by
AgNPs occurred at a concentration of 100 mg/mL resulting in a 4-log reduction; for a 4-log
reduction in biofilms under static conditions, a concentration of 500 mg/mL was required.
This difference shows that the formation of biofilms under shear forces can change their
structure and permeability. More recently, in a study performed by Appapalam et al.,
the antibiofilm action of aqueous extracts of Aerva lanata silver nanoparticles (AL-AgNPs)
against the most predominant and antibiotic-resistant DFU bacterial isolates (P. aeruginosa,
E. coli, S. aureus and Bacillus subtilis) was efficiently observed [229]. The minimum inhibitory
concentration (MIC) and minimum bactericidal concentration (MBC) of AL-AgNPs against
the DFU isolates were 5–15 mg/mL and 10–20 mg/mL, respectively. MIC and MBC of
AL-AgNPs were effective in destroying the preformed biofilms of DFU isolates [229]. Fur-
thermore, AL-AgNPs at MBC displayed an increased intracellular accumulation of reactive
oxygen species (ROS), membrane leakage, permeability, cell damage and genotoxicity in
the DFU isolates, which suggests an action on different targets and through different modes
of action [229].
Physical methods (e.g., irradiation, heat, high pressure) have also gained popularity
for their potential to induce resistance and are amenable for large scale applications [230].
Among these methods is PDT, which consists of the application of photosensitisers to
enhance the activity and transport of the antibiotics through of the biofilms [223,224]. At
a clinical level, PDT involves the topical application of a photosensitiser into the tissue,
followed by illumination to induce the formation of ROS [231]. PDT provides bacte-
rial inactivation and promotes wound healing, and can be used to manage the infection
and microbial colonisation of DFUs [232]. Recently, some studies have emerged on the
PDT approach to combat microbial biofilms [36,233,234], including the combination of
PDT with antibiotics [36,234,235]. For instance, Barra et al. showed that an earlier treat-
ment of a biofilm formed by Gram-positive bacteria (S. aureus and S. epidermidis) with
5-aminolevulinic acid (5-ALA)/PDT increased the susceptibility to gentamicin [234]. The
authors concluded that the ROS-mediated destruction, or significant damage, of the biofilm
may have enhanced the penetration and the subsequent action of the antibiotic [234]. The
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effects of PDT on bacterial viability within biofilms were evaluated after pre-incubation
with 5-ALA and irradiation with light fluences from 25 to 500 J/cm2. The viability of all
types of cells analysed decreased with the increase in the light dose administered [234].
Similarly, Li et al. exposed biofilms of S. aureus and MDR P. aeruginosa to indocyanine green
(ICG) photosensitiser and ethylenediamine tetraacetate (EDTA) metal chelating agent,
alone or combined with antibiotics (vancomycin and amikacin) followed by irradiation [34].
They observed that PDT-ICG + EDTA induced more bacterial death than PDT-ICG. After
treatment with PDT-ICG + EDTA followed by amikacin, biofilm detachment increased
and bacterial viability decreased. When PDT-ICG + EDTA-treated biofilms were combined
with vancomycin, the integrity of the cellular membranes was compromised, resulting
in a small percentage of living cells [36]. These results can be justified by the fact that
EDTA counteracts biofilms by chelating Mg2+ and Ca2+, which leads to cell wall instability
and the increased permeability of antibiotics and/or photosensitisers [236–238]; further-
more, EDTA also removes iron atoms, which are essential for microbial virulence and
pathogenicity [238].
8. Concluding Remarks and Challenges
People with diabetes have increased challenges in the wound healing process, which
puts them at a higher risk of developing chronic ulcers. DFUs have a significant impact on
the morbidity and mortality of patients as well as from an economic standpoint. This impact
is even greater when biofilms are present. Biofilms are not a new concept but continue
to be frequently undervalued despite their prominent role in the chronicity of diabetic
wounds. Biofilm-associated DFUs are usually treated as a simple infection, consisting of
basic wound care and the administration of current antibiotics, which is often insufficient.
Equally worrying is the lack of implementation of biofilm infection diagnosis tools. The
clinical outcomes for patients with DFUs become much more aggravated when biofilms
are present; therefore, the implementation of diagnostic techniques directed for identifying
biofilms in routine clinical practices is strongly suggested.
In recent years, some guidelines have emerged to direct the diagnosis and treatment of
biofilm infections. According to these guidelines, the treatment of biofilm-associated DFU
infections should be based on the principles of BBWC, with a combination of debridement
and the administration of antibiotics. Additionally, the use of algorithms for the detection
and treatment of biofilm-associated DFUs can be useful in clinical practice. To the best of our
knowledge, there are no algorithms that consider detection and treatment simultaneously.
Here, we proposed an algorithm that combines both to enable the detection of DFUs and
assist in choosing the treatment line to follow. However, when MDR bacteria are involved,
new strategies capable of inhibiting biofilm formation or dispersing preformed biofilms,
without conferring selective pressure, are required.
Despite the efforts, biofilm-associated DFUs are a problem which are still far from
being solved. Diabetes alone leads to dysfunctions in wound healing; therefore, it is not
accurate to affirm that if the biofilm is treated, the wound will heal. That said, better
evidence about the role of biofilms in DFU healing is necessary. Only in that way can new
treatment options emerge and translate into the clinical practice.
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